Baseline | After chemotherapy | After trastuzumab therapy | |
---|---|---|---|
LVEDVI (mL/m2) | 56.5 ± 9.9 | 55.9 ± 10.2 | 55.7 ± 10.3 |
LVESVI (mL/m2) | 20.3 ± 4.6 | 20.0 ± 5.1 | 20.2 ± 5.7 |
LVEF (%) | 63.9 ± 5.9 | 64.2 ± 6.7 | 63.8 ± 7.3 |
LVGLS (%) | −22.2 ± 2.2 | −20.2 ± 2.2* | −17.8 ± 2.3†‡ |
E (cm/sec) | 62.7 ± 7.7 | 61.4 ± 11.6 | 59.2 ± 11.8 |
e’ (cm/sec) | 8.3 ± 1.8 | 8.3 ± 1.7 | 7.9 ± 1.7 |
s’ (cm/sec) | 7.4 ± 1.0 | 7.3 ± 1.0 | 7.3 ± 1.1 |
E/e’ | 7.7 ± 1.2 | 7.6 ± 1.5 | 7.7 ± 1.8 |
LAVI (mL/m2) | 26.0 ± 3.9 | 26.1 ± 4.1 | 26.7 ± 4.0 |
PALS (%) | 33.8 ± 5.6 | 30.9 ± 5.7* | 28.0 ± 6.0†‡ |
LA conduit strain (%) | 19.8 ± 3.3 | 16.6 ± 3.0* | 15.0 ± 3.2†‡ |
LA booster strain (%) | 14.0 ± 2.3 | 14.3 ± 2.7 | 13.0 ± 2.8†‡ |
RVSP (mmHg) | 32.0 ± 7.3 | 30.8 ± 7.7 | 29.2 ± 8.1 |